Strengthening supply chain of anti-D immunoglobulins

Recommendations of the Executive Steering Group on Shortages and Safety of Medicinal Products to address anti-D immunoglobulin supply chain vulnerabilities

Availability of medicines before and during crises

Human medicines European public assessment report (EPAR): Neoatricon, dopamine hydrochloride, Date of authorisation: 27/05/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Tivdak, tisotumab vedotin, Date of authorisation: 28/03/2025, Revision: 2, Status: Authorised

Agenda of the HMPC meeting 7-9 July 2025

First EMA-ACRO bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 2 September 2025

Human medicines European public assessment report (EPAR): Lyvdelzi (previously Seladelpar Gilead), seladelpar lysine dihydrate, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Date of authorisation: 27/06/2025, Status: Authorised